Tevogen Bio's TVGN-489 Valued Up to $11 Billion

Warren, Monday, 8 September 2025.
Tevogen Bio Holdings Inc. announced a risk-adjusted net present value of $9-11 billion for its first clinical product, TVGN-489, potentially attracting significant investor interest and strategic partnerships.